Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | PRKACG | P22612 | 1/20 | 0.36 |
| ▸ | PRKACB | P22694 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219624 | 0.89 | DRD2 (0.51) | DRD2HTR2AHTR1ADRD3 | |
| SCHEMBL7219432 | 0.85 | DRD2 (0.68) | DRD2HTR2AHTR1ADRD3ADRA1A | |
| SCHEMBL7215989 | 0.82 | DRD2 (0.55) | DRD2HTR2AHTR1ANOTUMDRD3 | |
| SCHEMBL6796674 | 0.78 | DRD2 (0.63) | DRD2HTR2AHTR1ANOTUMDRD3 | |
| SCHEMBL6795568 | 0.77 | DRD2 (0.60) | DRD2HTR2AHTR1ANOTUMDRD3 | |
| SCHEMBL27585792 | 0.77 | HTR2A (0.63) | DRD2HTR2AHTR1ANOTUMDRD3 | |
| SCHEMBL21485228 | 0.77 | DRD2 (1.00) | DRD2HTR2AHTR1A | |
| SCHEMBL6795833 | 0.77 | DRD2 (0.62) | DRD2HTR2AHTR1ANOTUMDRD3 | |
| Hydrochloric Acid SCHEMBL21485258 | 0.76 | DRD2 (0.98) | DRD2HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL7081164 | 0.76 | DRD2 (0.61) | DRD2HTR2AHTR1ANOTUMDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552044-B2 | Dopamine receptors | H. LUNDBECK A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| EP-0946542-B1 | INDANE OR DIHYDROINDOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2002-10-09 | — | — | EP | disclosed |
| US-6352988-B2 | HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION | H. LUNDBECK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| US-20010021777-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-20010020095-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-06 | — | — | US | disclosed |
| CN-1246117-A | 1, 2-indane or indoline derivatives | LUNDBECK & CO AS H (DK) | 2000-03-01 | — | — | CN | disclosed |
| EP-0946542-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028293-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H.LUNDBECK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020095-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | DRD2 14/4885HTR2A 32/4885HTR1A 5/4885 |
| US-20010021777-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | DRD2 14/4885HTR2A 32/4885HTR1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.